News & Updates

Show Multimedia Only
SGLT-2 inhibitors may prevent dementia in adults with T2D
SGLT-2 inhibitors may prevent dementia in adults with T2D
07 Sep 2024 byStephen Padilla

Initiation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors results in a 35-percent reduced risk of dementia compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in individuals with type 2 diabetes (T2D) aged 40–69 years, according to a study. In addition, greater benefits are seen with longer treatment duration.

SGLT-2 inhibitors may prevent dementia in adults with T2D
07 Sep 2024
VTE incidence similar among common SGAs
VTE incidence similar among common SGAs
05 Sep 2024

The incidence of venous thromboembolism (VTE) does not appear to significantly differ among patients treated with second-generation antipsychotics (SGAs) such as risperidone, olanzapine, or aripiprazole, results of a study have shown.

VTE incidence similar among common SGAs
05 Sep 2024
Colchicine on par with NSAID for pericarditis prevention in HFrEF, CAD
Colchicine on par with NSAID for pericarditis prevention in HFrEF, CAD
04 Sep 2024
Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
04 Sep 2024 byAudrey Abella

In older patients with untreated mantle cell lymphoma (MCL), the addition of the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to bendamustine and rituximab (ABR) conferred a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a favourable trend for overall survival (OS), findings from the phase III ECHO trial have shown.

Add-on acalabrutinib prolongs PFS in older patients with untreated MCL
04 Sep 2024